Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can tracking tumor movement during radiation make treatment more precise?

NCT ID NCT05844761

Disease control Sponsor: Region Skane Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time

Summary

This trial investigates whether real-time motion management techniques—like triggered imaging and MLC tracking—can safely reduce the target margins used during radiotherapy for prostate and lung cancer. By adjusting the radiation beam to follow tumor movement, researchers aim to maintain or improve dose accuracy while potentially sparing healthy tissue. The study enrolls patients with localized prostate cancer or lung tumors and assesses both dosimetric and geometric accuracy from treatment data.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
radiotherapy with real-time motion management (triggered imaging or MLC tracking)
What this could lead to
If successful, this approach could make radiotherapy more precise, potentially reducing side effects by targeting tumors more accurately during movement.
What could go wrong
The trial is early-stage and focuses on technical accuracy rather than patient outcomes. The motion management techniques may not improve treatment in practice or could introduce new errors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 132 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2023

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: For prostate cancer patients: * Patients histologically proven prostate adenocarcinoma * Prostate specific antigen (PSA) obtained within three months prior to enrollment * Localised prostate cancer at any stage eligible for radiotherapy: i.e. any T- or Gleason stage, but no pelvic lymph nodes can be included within the target to be treated * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Ability to understand and the willingness to sign a written informed consent document. * Hypofractionated radiation therapy (HYPO) fractionated patients with a prescribed dose of 42.7Gy in 7 fractions. * MRIOnly workflow meaning synthetic generated CT based on Magnetic resonance imaging (MRI) * Patients over 40 years old For lung cancer patients: * Lung cancer or localised metastatic disease from other cancer diagnoses, accepted for stereotactic radiotherapy to 45Gy in 3 fractions * Lesion distinguishable on Computer Tomography and where the majority of adjacent tissue is the lung. * Ability to understand and the willingness to sign a written informed consent document. * Is able to perform treatment simulation Exclusion Criteria: For prostate cancer patients: * Patient must have three gold fiducial markers inserted in the prostate * Patients with artificial Hip(s), lumbar spinal surgical rods or other large metallic pelvic implants * Patients with overlapping implanted gold fiducials in X-ray imaging * Unfeasible to track fiducials with kv imaging/existing online imaging systems For lung cancer patients: * Previous treatment with radiotherapy for lung cancer or lung metastasis * Idiopathic lung fibrosis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer of lung are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung cancer lung carcinoma lung neoplasm prostate adenocarcinoma prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer of lung Cancer of prostate Lung metastasis

Contacts and locations

Locations

  • Skåne University Hospital

    Lund, Skåne County, 21185, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.